Techulon, an early stage life sciences company, has signed an agreement with Nacalai USA and its parent company Nacalai Tesque, for distribution of its Glycofect Transfection Reagent platform products in Japan.
Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest and is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics, said the companies.
The Glycofect family of reagents has a biodegradable composition that provides for efficacious delivery with very low toxicity in key cell types.
Techulon president Frank Akers said they are pleased to have Nacalai represent Techulon in Japan and they look forward to expand their business in the market.
Nacalai Tesque is a manufacturer and distributor of life science and chemical research reagents in Japan.